FIGURE LEGENDS
Figure 1. COVID-19 vaccination increased cross-reactive antibody
responses against other Betacoronaviruses. (A) Pre- and post-
vaccination antibody responses of BNT vaccinees (n=20) to the S and N
proteins of different human coronaviruses, Wilcoxon test was used to
compare the pre and post-vaccination antibody response. (B) Pre- and
post- vaccination antibody responses of CV vaccinees (n=21) to the S and
N proteins of different human coronaviruses, Wilcoxon test was used to
compare the pre and post-vaccination antibody response. (C) Differences
between BNT and CV vaccinees in the post-vaccination antibody responses
against the S and N proteins of different human coronaviruses,
Mann-Whitney test was used to compare antibody responses of BNT and CV
vaccinees.
Figure 2. Correlation between post-vaccination antibody response
against SARS-CoV-2 versus antibody response against other human
coronaviruses. (A) Post-vaccination antibody response against
SARS-CoV-2 versus pre-vaccination antibody responses against other
HCoVs. (B) Post-vaccination antibody response against SARS-CoV-2 versus
post- vaccination antibody responses against other HCoVs. The Spearman
coefficient were shown, * p<0.05, ** p<0.01.
Figure 3. SARS-CoV-2 infection increased cross-reactive antibody
responses against MERS-CoV. (A) Antibody responses against MERS-CoV S1,
S2, or N proteins detected from sera of healthy donors collected in 2019
prior to the COVID-19 pandemic (control sera, n=20), subjects infected
with SARS-CoV-2 without vaccination history (infected, n=20), subjects
infected with SARS-CoV-2 followed by 2-doses CV vaccination (infected +
CV, n=10), subjects infected with SARS-CoV-2 followed by 2-doses BNT
vaccination (infected + BNT, n=10), subjects vaccinated with 2-doses of
CV followed by SARS-CoV-2 infection (CV + infected, n=10), subjects
vaccinated with 2-doses of BNT followed by SARS-CoV-2 infection (BNT +
infected, n=10). The threshold AUC values (mean+3SD) determined from the
pre-pandemic sera were shown in dotted lines. (B) Neutralizing antibody
response against MERS-CoV were determined using the ppNT assay. In
addition to the pre-pandemic sera and convalescent sera tested above, we
also determined neutralizing antibody responses against MERS-CoV among
those who have been vaccinated with 3-doses of BNT (n=20) or CV (n=20)
without a history of SARS-CoV-2 infection. Sera were diluted at 1:10
dilution and any sample with ≥ 90% inhibition was considered positive.